Biotech Values

[Mufaso]

rfj1862 - ARAV- FWIW I looked at Aravive and decided to invest yesterday after you suggested it was worth a look . I found this KOL webcast from May 24th to be compelling not only for the content but also for the pure enthusiasm projected by the KOL's presenting:

https://ir.aravive.com/events/event-details/key-opinion-leader-kol-virtual-event-highlighting-batiraxcept-potential

Also- here is an updated poster to the abstract link you posted that has a few more graphics and an updated conclusion (note the updated qualifier on clinical activity). I highlighted several things that increased my confidence that batiraxcept is viable drug that will be commercially successful.

https://www.urotoday.com/conference-highlights/asco-2023/asco-2023-kidney-cancer/144813-asco-2023-phase-2-study-of-batiraxcept-as-monotherapy-in-combination-with-cabozantinib-and-in-combination-with-cabozantinib-and-nivolumab-in-patients-with-advanced-clear-cell-renal-cell-carci


This phase II trial (NCT04300140) tested batiraxcept at a dose of 15 mg/kg every 2 weeks in 3 distinct cohorts:

Cohort 1: Batiraxcept monotherapy in patients with relapsing disease and no curative options (n=10)
Cohort 2: Batiraxcept plus cabozantinib 60 mg daily in patients with at least 1 prior therapy (n=25)
Cohort 3: Batiraxcept plus cabozantinib 40 mg daily and nivolumab 240 q2w or 480 mg q4w in the 1st line setting (n=11)

An ORR, defined as either a complete or partial response, was observed in none of the patients in Cohort 1, compared to 36% and 55% of patients in Cohorts 2 and 3, respectively. One patient (10%) in Cohort 1 had stable disease. The median PFS was 1.8, 7.2, and 7.6 months, respectively.

Dr. Beckermann concluded that batiraxcept monotherapy is well-tolerated but has limited clinical activity in heavily pre-treated patients with relapsing disease and no other curative options. Batiraxcept-based combinations demonstrated efficacy and tolerability in both treatment-naïve patients and those with at least 1 prior therapy. Given the encouraging safety and efficacy signals, batiraxcept + cabozantinib will be further studied in a phase 3 trial of ccRCC patients in the ≥2nd line setting, whose disease has progressed on prior immunotherapy and VEGF-TKI treatment. Exploratory analysis for a baseline serum soluble AXL/GAS6 ratio biomarker was found to predict clinical activity in the phase 1b study evaluating batiraxcept + cabozantinib in patients who had failed 1st line therapies; a similar analysis using this biomarker is ongoing for this patient population.